SciSparc Ltd.
(NASDAQ : SPRC)

( )
SPRC PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson -0.74%178.190.7%$1350.94m
MRKMerck & Co., Inc. 0.21%92.610.7%$1211.55m
PFEPfizer Inc. -1.20%51.680.9%$1096.02m
LLYEli Lilly & Co. 0.74%327.131.1%$1026.00m
BMYBristol-Myers Squibb Co. -1.13%75.971.0%$991.64m
ABBVAbbVie, Inc. 0.03%153.851.9%$959.73m
AZNAstraZeneca Plc -0.67%65.511.0%$470.96m
SGENSeagen Inc. -1.85%176.775.7%$326.06m
GSKGSK Plc -1.01%43.310.2%$272.45m
TPTXTurning Point Therapeutics, Inc. 0.05%75.150.0%$199.28m
HZNPHorizon Therapeutics Plc 2.38%82.765.4%$174.09m
NVSNovartis AG -0.11%84.270.2%$172.25m
MRTXMirati Therapeutics, Inc. 1.10%71.961.6%$150.81m
ALNYAlnylam Pharmaceuticals, Inc. 1.67%150.738.1%$150.31m
NVONovo Nordisk A/S -0.40%111.190.1%$148.30m

Company Profile

SciSparc Ltd. is a clinical stage pharmaceutical company, which focuses on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The firm initiated two internal drug development programs based on repurposing an FDA approved synthetic cannabinoid (dronabinol): Joint Pharma developing THX-TS01 targeted to the treatment of TS and Brain Bright Pharma developing THX-ULD01 targeted to the high value and under-served market of MCIs. Its products include SCI-110, SCI-210, SCI-160, and CannAmide. The company was founded on August 23, 2004 and is headquartered in Tel Aviv, Israel.